<DOC>
	<DOCNO>NCT00603733</DOCNO>
	<brief_summary>The purpose study demonstrate new modified oral extended-release Pentasa速 500mg tablet least efficacious currently market Pentasa速 500mg tablet active mild moderate Ulcerative Colitis ( UC ) also maintenance quiescent disease .</brief_summary>
	<brief_title>Canadian Active &amp; Maintenance Modified Pentasa Study</brief_title>
	<detailed_description>A multi-centre , randomize , double-blind , non-inferiority trial compare efficacy safety new modified oral extend release Pentasa速 ( mesalamine ) 500 mg tablet currently market Pentasa速 ( mesalamine ) 500 mg tablet subject active mild moderate ulcerative colitis treat 4 g/day 8 week maintenance remission ulcerative colitis subject treat 2 g/day 24 week . The study involve male non-pregnant female subject age 18 75 year . Subjects randomise entry trial , remission end 8-week Active Phase 4-week Run-in Phase , eligible enrolment 24-week Maintenance Phase , remain original randomise treatment .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Inclusion Criteria Active phase : Newly diagnose recurrent , mild moderate Ulcerative Colitis patient . Extent colonic involvement confirm within past 36 month UCDAI score least 3 great 8 score least 1 endoscopy Screening test rule abnormality stool , heart kidney . Male nonpregnant female 18 75 year . Women childbearing potential use efficacious contraception judge investigator . Written informed consent give . Inclusion Criteria Maintenance phase : Newly recruit subject document mild moderate UC enter Runin Phase : clinical remission least 1 month maximum 3 year , receive 5ASA 1.4 2.5 g/day maintenance quiescent disease Subjects Active Phase : meeting remission criterion 8week active period Extent colonic involvement confirm within past 36 month colonoscopy In complete remission entry Maintenance Phase , define ) score 0 1 stool frequency ; ii ) score 0 rectal bleeding ; iii ) score 0 endoscopy finding ; iv ) Physician 's Global Assessment ( PGA ) score 0 1 Screening test rule abnormality stool , heart kidney . Use 5ASA product dose &gt; 2.5g/day within 7 day prior entry . Proctitis , short bowel syndrome , prior bowel surgery , severe UC , form Inflammatory Bowel Disease Infectious diseases , parasite , bacterial pathogen Allergy aspirin salicylate Liver kidney abnormality Alcohol drug abuse Pregnancy Cancer Bleeding disorder , ulcer , autoimmune disease Mental disorder Participation clinical trial last 30 day Inability fill diary card / comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>5-Aminosalicylate</keyword>
</DOC>